Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology

27-09-2024 | IL-23 Inhibitor | Research Letter

Real-World Evidence on Dose Spacing of IL-23 Inhibitors in the Treatment of Psoriasis

Authors: Martim Luz, Tiago Torres

Published in: American Journal of Clinical Dermatology

Login to get access

Excerpt

IL-23 inhibitors (IL-23i) have significantly advanced psoriasis management due to their high efficacy, favorable safety profile, and long-term effectiveness and persistence [1]. Evidence from clinical trials and real-world data has demonstrated that, in a subgroup of patients, it is feasible to extend the dosing interval of IL-23i while maintaining efficacy and reducing the frequency of administration [2, 3]. We evaluated the feasibility of dose spacing with IL-23i treating psoriatic patients and identified key patient characteristics supporting this approach. …
Appendix
Available only for authorised users
Literature
1.
Vu A, Ulschmid C, Gordon KB. Anti-IL 23 biologics for the treatment of plaque psoriasis. Expert Opin Biol Ther. 2022;22(12):1489–502.CrossRefPubMed
2.
Gisondi P, Maurelli M, Bellinato F, Girolomoni G. Is risankizumab as needed administration a good option for patients with plaque psoriasis? J Eur Acad Dermatol Venereol. 2022;36(9):e713–5.CrossRefPubMed
3.
4.
Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649–58.CrossRefPubMed
5.
Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–31.CrossRefPubMed
6.
Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, et al. Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891–904.CrossRefPubMed
7.
Queiro R, Seoane-Mato D, Laiz A, Galindez Agirregoikoa E, Montilla C, Park HS, Pinto Tasende JA, Bethencourt Baute JJ, Joven Ibanez B, Toniolo E, et al. Severe disease in patients with recent-onset psoriatic arthritis. Prediction model based on machine learning. Front Med (Lausanne). 2022;9:891863.CrossRefPubMed
8.
Mehta H, Mashiko S, Angsana J, Rubio M, Hsieh YM, Maari C, Reich K, Blauvelt A, Bissonnette R, Munoz-Elias EJ, et al. Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab. J Invest Dermatol. 2021;141(7):1707-1718 e1709.CrossRefPubMed
9.
Atalay S, van den Reek J, Otero ME, Njoo MD, Mommers JM, Ossenkoppele PM, Koetsier MI, Berends MM, van de Kerkhof PCM, Groenewoud HMM, et al. Health economic consequences of a tightly controlled dose reduction strategy for adalimumab, etanercept and ustekinumab compared with standard psoriasis care: a cost-utility analysis of the CONDOR study. Acta Derm Venereol. 2020;100(19):adv00340.CrossRefPubMed
Metadata
Title
Real-World Evidence on Dose Spacing of IL-23 Inhibitors in the Treatment of Psoriasis
Authors
Martim Luz
Tiago Torres
Publication date
27-09-2024
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-024-00894-9